Spanish company Noventure has signed an agreement with Pierre Fabre Pharma Italy for the commercialisation of its Aprotecol device in the country.
Designed to prevent and treat bloating and intestinal colic, Aprotecol is a CE-Marked Class IIa medical device developed for infants and young children.
Abdominal tension and colic can occur due to a variety of factors, including intestinal mucosa leakage and gas-producing bacteria growth in the intestines.
Noventure CEO Luciano Conde said: “Aprotecol is an innovative product that will help to improve the quality of life of young patients across Italy affected by colic and bloating, as well as their parents.
“We firmly believe that partnering with Pierre Fabre, whose commitment to children’s healthcare is recognised worldwide, represents a great opportunity for Noventure to further disseminate its innovative barrier technology.”
Available as an oral oily suspension, Aprotecol supports the mucosal barrier and rebalances the intestinal flora.
Pierre Fabre is expected to release Aprotecol in January.
Pierre Fabre Pharma Italy general manager Charles-Henri Bodin said: “Aprotecol is a great opportunity for Pierre Fabre to reinforce its position in paediatrics in Italy.
“Our teams are prepared and highly motivated to offer Italian paediatricians this innovative solution to treat their young patients.”
Noventure develops natural polymer products based on its barrier technology for gastrointestinal, paediatrics, urogynecology, allergy, and dermatology sectors.
The firm operates by licensing medical devices to partner companies and includes a network of distributors and partners across more than 40 countries.